Barton Shane 4
4 · BioAge Labs, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
BioAge (BIOA) Principal Accounting Officer Barton Shane Receives Award
What Happened
- Barton Shane, BioAge Labs' Principal Accounting Officer, was granted a derivative award of 45,000 shares on Feb 17, 2026. The award was reported at a $0.00 acquisition price (no cash paid).
- This was an award/grant (SEC transaction code A), not an open-market buy or sale.
Key Details
- Transaction date: 2026-02-17; Filing date: 2026-02-19 (Form 4 appears timely).
- Price: $0.00 per share; Total reported cost: $0.
- Vesting: The award vests 1/48th monthly, with the first tranche vested on Feb 1, 2026, and monthly vesting thereafter, subject to continued service (footnote F1).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.
Context
- This is a time-based derivative award (commonly RSUs or option-style awards); vesting over 48 months means shares will be delivered (or become exercisable) gradually if the insider remains employed.
- Awards are routine compensation and do not by themselves signal intent to buy or sell shares on the open market.
Insider Transaction Report
Form 4
Barton Shane
Principal Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-02-17+45,000→ 45,000 totalExercise: $19.63Exp: 2036-02-16→ Common Stock (45,000 underlying)
Footnotes (1)
- [F1]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Signature
/s/ Dov A. Goldstein as attorney-in-fact|2026-02-19